These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 28185687)

  • 1. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
    Cabel L; Proudhon C; Mariani P; Tzanis D; Beinse G; Bieche I; Pierga JY; Bidard FC
    Eur J Surg Oncol; 2017 May; 43(5):949-962. PubMed ID: 28185687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free circulating tumor DNA in cancer.
    Qin Z; Ljubimov VA; Zhou C; Tong Y; Liang J
    Chin J Cancer; 2016 Apr; 35():36. PubMed ID: 27056366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
    Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
    J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsy for the Management of Patients with Colorectal Cancer.
    Yamada T; Matsuda A; Koizumi M; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Yokoyama Y; Hara K; Hotta M; Matsumoto S; Yoshida H
    Digestion; 2019; 99(1):39-45. PubMed ID: 30554222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
    Takai E; Yachida S
    World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in circulating nucleic acids in oncology.
    Otandault A; Anker P; Al Amir Dache Z; Guillaumon V; Meddeb R; Pastor B; Pisareva E; Sanchez C; Tanos R; Tousch G; Schwarzenbach H; Thierry AR
    Ann Oncol; 2019 Mar; 30(3):374-384. PubMed ID: 30753271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.
    Bidard FC; Madic J; Mariani P; Piperno-Neumann S; Rampanou A; Servois V; Cassoux N; Desjardins L; Milder M; Vaucher I; Pierga JY; Lebofsky R; Stern MH; Lantz O
    Int J Cancer; 2014 Mar; 134(5):1207-13. PubMed ID: 23934701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Biomarkers for Prediction of Treatment Response.
    Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsies in Oncology and the Current Regulatory Landscape.
    Strotman LN; Millner LM; Valdes R; Linder MW
    Mol Diagn Ther; 2016 Oct; 20(5):429-36. PubMed ID: 27324559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of circulating copy number variant detection for cancer screening.
    Molparia B; Nichani E; Torkamani A
    PLoS One; 2017; 12(7):e0180647. PubMed ID: 28686671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.